These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 35286596)

  • 21. Quadruple immunosuppression with basiliximab, tacrolimus, mycophenolate mofetil and prednisone is safe and effective for renal transplantation.
    Miura M; Harada H; Fukuzawa N; Iwami D; Taniguchi A; Seki T; Togashi M; Ogawa Y; Satoh H; Hirano T
    Clin Transplant; 2005; 19 Suppl 14():54-8. PubMed ID: 15955170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protocol biopsies in pediatric renal transplant recipients on cyclosporine versus tacrolimus-based immunosuppression.
    Aoun B; Decramer S; Vitkevic R; Wannous H; Bandin F; Azema C; Callard P; Brocheriou I; Ulinski T
    Pediatr Nephrol; 2013 Mar; 28(3):493-8. PubMed ID: 23111894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daclizumab as escape therapy for late acute kidney rejection in the presence of FK506 nephrotoxicity.
    Oberholzer J; Triponez F; Martin PY; Williamson C; Morel P
    Transpl Int; 2000; 13(2):169-71. PubMed ID: 10836657
    [No Abstract]   [Full Text] [Related]  

  • 24. Tacrolimus dosing in mycophenolate-treated patients--can we get away with less?
    de Fijter JW
    Transplantation; 2011 Jul; 92(1):10-1. PubMed ID: 21654351
    [No Abstract]   [Full Text] [Related]  

  • 25. Oral ulcerations as a sequela of tacrolimus and mycophenolate mofetil therapy.
    Philipone E; Rockafellow A; Sternberg R; Yoon A; Koslovsky D
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2014 Dec; 118(6):e175-8. PubMed ID: 25457894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Four-year follow-up of the European Tacrolimus Multicenter Renal Study.
    Mayer AD
    Transplant Proc; 1999 Nov; 31(7A):27S-28S. PubMed ID: 10576038
    [No Abstract]   [Full Text] [Related]  

  • 28. Tacrolimus based immunosuppression.
    First MR
    J Nephrol; 2004; 17 Suppl 8():S25-31. PubMed ID: 15599882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased early rejection rate after conversion from tacrolimus in kidney and pancreas transplantation.
    Barone GW; Ketel BL; Abul-Ezz SR; Lightfoot ML
    JOP; 2002 Mar; 3(2):49-53. PubMed ID: 11884766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calcineurin inhibitors in pediatric renal transplant recipients.
    Filler G
    Paediatr Drugs; 2007; 9(3):165-74. PubMed ID: 17523697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus.
    Friemann S; Feuring E; Padberg W; Ernst W
    Transplant Proc; 1998 Jun; 30(4):1240-2. PubMed ID: 9636504
    [No Abstract]   [Full Text] [Related]  

  • 32. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
    Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
    Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two Decades of Tacrolimus in Renal Transplant: Basic Science and Clinical Evidences.
    Shrestha BM
    Exp Clin Transplant; 2017 Feb; 15(1):1-9. PubMed ID: 27938316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?
    van Gelder T; Hesselink DA
    Clin Pharmacol Ther; 2010 Jun; 87(6):640-1. PubMed ID: 20485320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A case of tacrolimus (FK506)-induced pancreatitis and fatality 2 years postcadaveric renal transplant.
    Ogunseinde BA; Wimmers E; Washington B; Iyob M; Cropper T; Callender CO
    Transplantation; 2003 Jul; 76(2):448. PubMed ID: 12883222
    [No Abstract]   [Full Text] [Related]  

  • 37. Primary immunosuppression with tacrolimus in kidney transplantation: three-year follow-up in a single center.
    Kim HC; Hwang EA; Han SY; Park SB; Kim HT; Cho WH
    Transplant Proc; 2004 Sep; 36(7):2082-3. PubMed ID: 15518753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidermoid cysts in kidney transplant patients receiving tacrolimus.
    Verma S; Batra R; Gupta S; Zouboulis CC
    Dermatol Ther; 2020 Mar; 33(2):e13259. PubMed ID: 32043723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment-Refractory Mania with Psychosis in a Post-Transplant Patient on Tacrolimus: A Case Report.
    Ithman M; Malhotra K; Bordoloi M; Singh G
    Clin Med Res; 2018 Jun; 16(1-2):47-49. PubMed ID: 29776917
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinically Significant Drug Interaction Between Clotrimazole and Tacrolimus in Pancreas Transplant Recipients and Associated Risk of Allograft Rejection.
    Viesselmann CW; Descourouez JL; Jorgenson MR; Radke NA; Odorico JS
    Pharmacotherapy; 2016 Mar; 36(3):335-41. PubMed ID: 26877191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.